View Older Stories

Aug 4, 2011 10:58AM Notable Analyst Rating Changes 08/04: (EMC) (MCD) (TIF) Upgraded; (DNDN) (WFR) (WLT) Downgraded

Aug 4, 2011 10:21AM UPDATE - Needham & Company downgrades Dendreon (DNDN) from Buy to Hold; Strong Science, Modest Adoption but Lowering our PROVENGE Sales Ests Given N-T Hurdles

Aug 4, 2011 08:16AM Needham & Company Downgrades Dendreon (DNDN) to Hold

Jul 1, 2011 07:41AM Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); Three Events Help Facilitate the One Goal of Increasing PROVENGE Sales

Jun 8, 2011 08:03AM Needham & Company Maintains a 'Buy' on Dendreon (DNDN); ASCO Mtg Presentations Highlight PROVENGE Clinical Benefits Beyond Overall Survival

May 19, 2011 08:24AM Needham & Co Highlights Seattle Genetics (SGEN), Pharmacyclics (PCYC), and Dendreon (DNDN) Ahead of ASCO

May 3, 2011 07:49AM Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); Company Management Executing on Sales/Manufacturing Plans to Expand PROVENGE Use

Apr 12, 2011 07:39AM Needham & Company on Biotechnology & Life Sciences: Oncology / Hematology Review from the 2011 Needham Healthcare Conference

Mar 31, 2011 07:44AM Needham & Company Maintains a 'Buy' on Dendreon (DNDN); Did You Get the Memo? CMS Supports the Coverage of PROVENGE for On-Label Use

Mar 2, 2011 07:54AM Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); PROVENGE Marches On, with Manufacturing Plans on Schedule

Jan 7, 2011 03:07PM Needham & Company reiterates a 'Buy' on Dendreon (DNDN); Why Wait? Early New Year Plans to Expand PROVENGE Marketing in the US Alongside Expanded Manufacturing Capacity

Jan 5, 2011 08:05AM Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); PROVENGE Demand > Supply, Manufacturing on Track, Reimbursement Concerns Eased

Nov 18, 2010 03:54PM Analysts Remain Bullish on Dendreon (DNDN) Following Positive MEDCAC Review

Nov 18, 2010 07:52AM Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); Clear Messages Emerged That On-Label PROVENGE Use Consistent with Survival Benefit

Aug 4, 2010 08:11AM Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); Potential Product Revenue and Manufacturing Build-Out

Jul 12, 2010 07:54AM Needham & Company Reiterates a 'Buy' Rating Dendreon (DNDN); 2Q10 Earnings Preview

Apr 30, 2010 02:03PM Needham & Company Maintanis a 'Buy' on Dendreon (DNDN); Raises PT to $62

Apr 30, 2010 01:47PM Wall Street Giddy About Dendreon (DNDN) After Provenge Approval; Where Are Shares Headed?

Apr 30, 2010 08:47AM Needham & Company Raises Price Target On Dendreon (DNDN) to $62

Apr 14, 2010 11:03AM Notable Analyst Rating Changes 04/14: AIB, ERIC, MCD, CREE Upgraded; POT/MOS, TWC/DTV, DNDN, NOK Downgraded

Mar 4, 2010 08:48AM Needham & Company Says Updated PROVENGE Data from Dendreon (DNDN) "Further Outline the Robustness"

Jan 7, 2010 10:54AM Notable Analyst Rating Changes 1/7: BAC, SHLD, THC, IT, ZUMZ, CITP Upgraded; RAI, AA, RAD, WEN, BEXP Downgraded

Dec 11, 2009 06:47AM Dendreon (DNDN) Prices 15M Common Offering at $24.75/Share

Jul 23, 2009 10:01AM Needham Comments on "Who's Next" In Biotech After Bristol-Myers (BMY) Buys Medarex (MEDX)

May 18, 2009 10:16AM Needham Discusses Next Steps For Dendreon's (DNDN) PROVENGE

May 11, 2009 11:19AM Dendreon (DNDN) Sees Continued Upside On 'Table-Pounding' Analyst Comments

Apr 29, 2009 10:59AM Needham Upgrades Dendreon (DNDN) To Buy, With 'Street High' $38 Price Target

Apr 14, 2009 12:56PM Needham & Co Positive About Dendreon (DNDN) PROVENGE Results, Maintains Hold On Valuation

View Older Stories